Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple
tumor types, providing unprecedented survival in some patients. Despite the characteristic …

Abstract Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall
survival of a subset of patients across multiple solid tumour types, but other patients can …

Purpose Immune checkpoint inhibitors are associated with clinical benefit in lung cancer.
However, response patterns to immunotherapy, including pseudoprogression and …

Oncogene-driven non small cell lung cancer (NSCLC) is a distinct entity in thoracic
oncology. The availability of effective target therapies, like EGFR inhibitors or ALK inhibitors …

Checkpoint blockade therapy has shown significant therapeutic benefits and resulted in
durable responses in patients with various tumors. However, accumulating evidence has …

The immune checkpoint inhibitors (ICIs), by targeting cytotoxic-T-lymphocyte-associated
protein 4, programmed cell death 1 (PD-1), or PD-ligand 1, have dramatically changed the …

Background Co-occurring genomic alterations identified downstream main oncogenic
drivers have become more evident since the introduction of next-generation sequencing …

The current treatment options for epidermal growth factor receptor (EGFR) mutation‑positive
lung cancer in the elderly with tyrosine kinase inhibitor (TKI) resistance are limited. Although …

Lung cancer represents a considerable global health threat, leading the list in terms of
cancer-related deaths worldwide. An important proportion of lung cancer cases occur within …

Objective: Targeted next-generation sequencing (t-NGS) has revolutionized clinical
diagnosis allowing multiplexed detection of genomic alterations. This study evaluated the …